Your browser doesn't support javascript.
loading
Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.
Kappel, Coralea; Jiang, Di Maria; Wong, Bryan; Zhang, Tong; Selvarajah, Shamini; Warner, Evan; Hansen, Aaron R; Fallah-Rad, Nazanin; Sacher, Adrian G; Stockley, Tracy L; Bedard, Philippe L; Sridhar, Srikala S.
Afiliação
  • Kappel C; Department of Medicine, McMaster University, Hamilton, Canada.
  • Jiang DM; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada. Electronic address: di.jiang@uhn.ca.
  • Wong B; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
  • Zhang T; Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
  • Selvarajah S; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Warner E; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Hansen AR; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
  • Fallah-Rad N; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
  • Sacher AG; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
  • Stockley TL; Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Bedard PL; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
  • Sridhar SS; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
Clin Genitourin Cancer ; 20(3): 278-284, 2022 06.
Article em En | MEDLINE | ID: mdl-35337750
ABSTRACT

INTRODUCTION:

While comprehensive genomic profiling (CGP) data is becoming increasingly important in the management of prostate cancer, it remains under-utilized in the setting of metastatic castrate sensitive prostate cancer (mCSPC). We aimed to explore the feasibility and potential utility of CGP in mCSPC. PATIENTS AND

METHODS:

Patients with mCSPC were prospectively recruited at the Princess Margaret Cancer Centre to the OCTANE trial (NCT02906943). The objective was to assess the feasibility of profiling archival standard diagnostic tumor tissue using next generation sequencing with a custom hybridization capture DNA-based or a targeted DNA/RNA amplicon-based panel. Clinical data were extracted from electronic health records.

RESULTS:

Among 39 mCSPC patients enrolled, 21 (54%) had sufficient archival tissue for CGP. Most had high volume (71%) or de novo (71%) mCSPC, with the majority being androgen deprivation therapy (ADT) naïve. In total, 62% of patients had a pathogenic and/or a likely pathogenic variant, many of which involved DNA damage repair (DDR, 19%), cell cycle (24%), and Androgen Receptor (AR, 10%) pathways. After median follow-up of 32.1 months, 18 of 21 patients progressed, with median time to mCRPC of 14.3 months (95% CI 10.2-21.0). Patients with AR and DDR variants seemed to have shorter median time to mCRPC; 10.2 (95% CI 9.50-NR) and 10.3 months (95% CI 6.6-14.3) respectively.

CONCLUSION:

In this cohort of highly treatment resistant mCSPC, most of which were ADT-naïve, CGP using archival tumor tissue was feasible for over half of patients, and 62% of patients profiled had a pathogenic and/or a likely pathogenic variant. The presence of de novo variants provides biological basis for evaluating intensification strategies of systemic therapy. This highlights the potential role of routine CGP in biomarker development and clinical trial design in the setting of mCSPC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Clin Genitourin Cancer Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Clin Genitourin Cancer Assunto da revista: NEOPLASIAS / UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá